Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Amortizatization of Intangibles (2016 - 2024)

Lineage Cell Therapeutics (LCTX) has 15 years of Amortizatization of Intangibles data on record, last reported at $22000.0 in Q1 2024.

  • For Q1 2024, Amortizatization of Intangibles fell 33.33% year-over-year to $22000.0; the TTM value through Dec 2024 reached $22000.0, down 83.08%, while the annual FY2024 figure was $22000.0, 83.08% down from the prior year.
  • Amortizatization of Intangibles reached $22000.0 in Q1 2024 per LCTX's latest filing, down from $32000.0 in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $1.1 million in Q3 2020 and bottomed at -$1.0 million in Q4 2020.
  • Average Amortizatization of Intangibles over 5 years is $31142.9, with a median of $32500.0 recorded in 2023.
  • The widest YoY moves for Amortizatization of Intangibles: up 3218.75% in 2020, down 1540.0% in 2020.
  • A 5-year view of Amortizatization of Intangibles shows it stood at -$1.0 million in 2020, then surged by 111.11% to $112000.0 in 2021, then tumbled by 111.61% to -$13000.0 in 2022, then surged by 346.15% to $32000.0 in 2023, then plummeted by 31.25% to $22000.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Amortizatization of Intangibles were $22000.0 in Q1 2024, $32000.0 in Q4 2023, and $33000.0 in Q3 2023.